CD2+ Lymphocyte Subsets and Bladder Cancer Relapse
Author Information
Author(s): Reyes E, Carballido J, Manzano L, Moltó L, Olivier C, Alvarez-Mon M
Primary Institution: University Hospital ‘Principe de Asturias’, University of Alcalá, Madrid, Spain
Hypothesis
Are there differences in T-lymphocyte subsets and their response in bladder cancer patients treated with BCG based on their clinical outcomes?
Conclusion
The study found differences in T-lymphocyte subset distribution and activation in bladder cancer patients treated with BCG, which may relate to their clinical response.
Supporting Evidence
- Different T-lymphocyte subset distributions were found in patients based on their clinical response to BCG treatment.
- The study observed a transitory variation in T-lymphocyte subset distribution after BCG instillations.
Takeaway
This study looked at how certain immune cells behave in bladder cancer patients who received a specific treatment, finding that those who did well had different immune responses than those who had a relapse.
Methodology
The study investigated T-lymphocyte subset distribution and proliferative responses in bladder cancer patients treated with BCG.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website